ClinicalTrials.gg

Program

hyaluronidase (human recombinant)

Also written as “Efgartigimod PH20 SC”, “efgartigimod PH20 SC” and “rHuPH20”.

Its studies are mostly in Diabetes Mellitus, Type 1 · Myasthenia Gravis · Primary Immunodeficiency Diseases · Dehydration · Multiple Myeloma, led by 7 companies.

Furthest: phase 4, since Oct 7, 202457 company-led studies, 14 open or runningNext primary completion: Mar 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
argenx2211 open or runningphase 4since Oct 7, 2024Feb 20, 2020Mar 2027phase 2 · NCT06655155
Halozyme Therapeutics200 open or runningphase 4since Apr 4, 2006Apr 4, 2006none ahead
Takeda60 open or runningphase 3since Dec 23, 2008Oct 29, 2008none ahead
Hoffmann-La Roche42 open or runningphase 2since Sep 11, 2017Sep 11, 2017Aug 31, 2029phase 2 · NCT07503340
Baxter Healthcare30 open or runningphase 4since Dec 10, 2008Dec 10, 2008none ahead
Fosun Pharma11 open or runningphase 1since Feb 24, 2026Feb 24, 2026none ahead
Johnson & Johnson10 open or runningphase 1since Aug 6, 2015Aug 6, 2015none ahead

Also a collaborator on its studies: BioLineRx.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Apr 4, 2006.

  1. Aug 14, 2024Phase 3 study in Myasthenia Gravisargenx · NCT06558279 · 141 enrolled · United States, Australia, Austria and more
  2. Oct 7, 2024Phase 4 study in Polyradiculoneuropathy, Chronic Inflammatory Demyelinatingargenx · NCT06637072 · 23 enrolled · United States
  3. Oct 22, 2024Phase 2 study in Scleroderma, Systemicargenx · NCT06655155 · 87 enrolled · United States, Argentina, Belgium and more
  4. Nov 10, 2024Phase 3 study in Primary Sjogrens Diseaseargenx · NCT06684847 · 631 enrolled · United States, Argentina, Australia and more
  5. Mar 27, 2025Phase 4 study in New Onset Generalized Myasthenia Gravis (gMG)argenx · NCT06909214 · 30 planned · United States
  6. Feb 24, 2026Fosun Pharma’s first study: phase 1 study in Healthy Adult MaleNew to Fosun PharmaFosun Pharma · NCT07484893 · 24 planned · China
  7. Mar 25, 2026Phase 2 study in Multiple Sclerosis, Relapsing-RemittingHoffmann-La Roche · NCT07503340 · 25 planned
  8. Apr 30, 2026Phase 3 study in Graves Diseaseargenx · NCT07570316 · 230 planned · United States, Georgia, United Kingdom
  9. May 13, 2026Phase 3 study in Graves Diseaseargenx · NCT07596849 · 230 planned · Belgium, Bulgaria, Canada and more
  10. Jun 18, 2026Phase 1 study in Multiple SclerosisHoffmann-La Roche · NCT07667322 · 75 enrolled · United States, Brazil, Mexico and more
  11. Jul 29, 2026Phase 2 study in Sjogrens Diseaseargenx · NCT07760818 · 75 planned
  12. Sep 29, 2026Primary completion moved from 2027-10-31 to 2027-12-31Date moved laterphase 3 · +2 months · NCT05296798
  13. Oct 2, 2026Primary completion moved from 2027-12-31 to 2028-06-15Date moved laterphase 3 · +5 months · NCT05296798
  14. Oct 19, 2026Primary completion moved from 2026-10-01 to 2027-10Date moved laterphase 3 · +12 months · NCT04812925

Ahead

  1. Mar 2027Primary completion: phase 2 study in Scleroderma, Systemicargenx · NCT06655155
  2. Apr 30, 2027Primary completion: phase 2 study in Polyradiculoneuropathy, Chronic Inflammatory Demyelinatingargenx · NCT04280718
  3. Jul 2027Primary completion: phase 3 study in Primary Sjogrens Diseaseargenx · NCT06684847
  4. Sep 2027Primary completion: phase 3 study in Myasthenia Gravisargenx · NCT06392386

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 57 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07760818Sjogrens Disease2Not yet recruitingargenxJul 28, 202875
NCT07667322Multiple Sclerosis · United States, Brazil, Mexico and more1Active, not recruitingHoffmann-La RocheSep 1, 202675
NCT07596849Graves Disease · Belgium, Bulgaria, Canada and more3RecruitingargenxJun 2028230
NCT07570316Graves Disease · United States, Georgia, United Kingdom3RecruitingargenxJun 2028230
NCT07503340Multiple Sclerosis, Relapsing-Remitting2Not yet recruitingHoffmann-La RocheAug 31, 202925
NCT07484893Healthy Adult Male · China1Not yet recruitingFosun PharmaAug 25, 202624
NCT06909214New Onset Generalized Myasthenia Gravis (gMG) · United States4RecruitingargenxAug 202630
NCT06684847Primary Sjogrens Disease · United States, Argentina, Australia and more3Active, not recruitingargenxJul 2027631
NCT06655155Scleroderma, Systemic · United States, Argentina, Belgium and more2Active, not recruitingargenxMar 202787
NCT06637072Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States4CompletedargenxFeb 19, 202623
NCT06558279Myasthenia Gravis · United States, Australia, Austria and more3Active, not recruitingargenxJan 12, 2026141
NCT06392386Myasthenia Gravis · United States, Australia, Belgium and more3RecruitingargenxSep 202712
NCT06307626Graves Ophthalmopathy · United States, Austria, Bulgaria and more3TerminatedargenxDec 15, 2025105
NCT06307613Graves Ophthalmopathy · United States, Australia, Belgium and more3TerminatedargenxDec 15, 2025102
NCT05979441Myositis · United States, Argentina, Austria and more3By invitationargenxSep 2028240
NCT05681481Pemphigoid, Bullous · United States, Australia, Bulgaria and more3TerminatedargenxMar 20, 202564
NCT05267600Pemphigoid, Bullous · United States, Australia, Bulgaria and more3CompletedargenxSep 13, 202498
NCT04812925Purpura, Thrombocytopenic, Idiopathic · United States, Argentina, Australia and more3Active, not recruitingargenxOct 2027173
NCT04818671Myasthenia Gravis · United States, Belgium, Czechia and more3CompletedargenxDec 31, 2024184
NCT04735432Myasthenia Gravis · United States, Belgium, Georgia and more3CompletedargenxNov 2, 2021110
NCT04687072Purpura, Thrombocytopenic, Idiopathic · United States, Argentina, Australia and more3CompletedargenxOct 9, 2023207
NCT04598477Pemphigus · United States, Australia, Bulgaria and more3TerminatedargenxMar 25, 2024183
NCT04598451Pemphigus · United States, Australia, Bulgaria and more3CompletedargenxAug 22, 2023222
NCT04564066Healthy Volunteers · Netherlands1CompletedargenxDec 24, 202054
NCT04280718Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Austria, Belgium and more2Active, not recruitingargenxApr 30, 2027229
NCT04045028Multiple Myeloma · United States, Korea, Republic of1TerminatedHoffmann-La RocheMar 28, 202341
NCT03281369Esophageal Neoplasms · United States, Australia, Israel and more2TerminatedHoffmann-La RocheOct 9, 2025219
NCT02519452Multiple Myeloma · United States, Denmark, France and more1CompletedJohnson & JohnsonDec 13, 2017120
NCT01848990Diabetes Mellitus, Type 1 · United States4CompletedHalozyme TherapeuticsFeb 2014456
NCT01756157Angioedemas, Hereditary · United States, Germany, Spain and more2CompletedTakedaSep 13, 201347
NCT01572012Healthy · United States1CompletedHalozyme TherapeuticsNov 201312
NCT01526733Diabetes Mellitus, Type 1 · United States4CompletedHalozyme TherapeuticsAug 201225
NCT01485796Primary Immunodeficiency Diseases · United States3CompletedTakedaJan 1, 201354
NCT01426763Angioedemas, Hereditary · United States2CompletedTakedaNov 28, 201112
NCT01275131Diabetes Mellitus, Type 1 · United States1CompletedHalozyme TherapeuticsDec 201145
NCT01194258Diabetes Mellitus, Type 2 · United States2CompletedHalozyme TherapeuticsAug 2011132
NCT01194245Diabetes Mellitus, Type 1 · United States2CompletedHalozyme TherapeuticsAug 2011135
NCT01175213Primary Immunodeficiency Diseases · United States3CompletedTakedaAug 6, 201366
NCT01120431Dehydration4WithdrawnBaxter HealthcareMay 20100
NCT01116102Dehydration · United States4TerminatedBaxter HealthcareMay 201020
NCT00979875Insulin Resistance · United States1CompletedHalozyme TherapeuticsFeb 201014
NCT00928447Dermatitis, Allergic Contact · United States2CompletedHalozyme TherapeuticsSep 13, 200922
NCT00916357Diabetes Mellitus, Type 2 · United States2CompletedHalozyme TherapeuticsNov 200923
NCT00883558Diabetes Mellitus, Type 1 · United States2CompletedHalozyme TherapeuticsFeb 201048
NCT00862849Diabetes Mellitus · United States1CompletedHalozyme TherapeuticsJun 200922
NCT00814320Primary Immunodeficiency Diseases · United States, Canada3CompletedTakedaNov 11, 201089
NCT00807963Risk Factors for or a Diagnosis of Osteoporosis · United States1CompletedHalozyme TherapeuticsSep 21, 200931
NCT00807885Dehydration · United States4CompletedBaxter HealthcareJan 2009100
NCT00782587Non-Muscle Invasive Bladder Neoplasms · United States1CompletedHalozyme TherapeuticsMar 200914
NCT00782106Primary Immunodeficiency Diseases · United States2CompletedTakedaNov 1, 200711
NCT00774800Diabetes Mellitus, Type 1 · United States2CompletedHalozyme TherapeuticsMar 200922
NCT00773175Dehydration · United States4CompletedHalozyme TherapeuticsNov 2009148
NCT00656370Healthy · United States4CompletedHalozyme TherapeuticsJan 30, 200815
NCT00593281Pain · United States3CompletedHalozyme TherapeuticsOct 200613
NCT00435604Healthy1CompletedHalozyme Therapeutics15
NCT00318643Urinary Bladder Neoplasms · United States2CompletedHalozyme TherapeuticsAug 11, 200927
NCT00311519Healthy · United States4CompletedHalozyme Therapeutics50

How it is read

Names in the registry

  • “Efgartigimod PH20 SC”, 12 entries
  • “efgartigimod PH20 SC”, 10 entries
  • “rHuPH20”, 5 entries
  • “Recombinant human hyaluronidase PH20 (rHuPH20)”, 4 entries
  • “recombinant human hyaluronidase”, 3 entries

Codes read as this program: RHUPH20.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.